BMPR2 germline mutation in chronic thromboembolic pulmonary hypertension

Lung

Volumn 192, Issue 4, 2014, Pages 625-627

  Feng, Yu Xuan ^a   Liu, Dong ^b   Sun, Ming Li ^b   Jiang, Xin ^c   Sun, Na ^b   Mao, Yi Min ^a   Jing, Zhi Cheng ^c  

^a HENAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^c FUWAI HOSPITAL   (China)

Author keywords

Bone morphogenetic protein receptor 2; Chronic thromboembolic pulmonary hypertension; Gene mutation

Indexed keywords

BERAPROST; BONE MORPHOGENETIC PROTEIN 2; SILDENAFIL; WARFARIN; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; BMPR2 PROTEIN, HUMAN; BONE MORPHOGENETIC PROTEIN RECEPTOR 2;

ADULT; ARTICLE; CASE REPORT; CENTRAL VENOUS PRESSURE; CHEST TIGHTNESS; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; CONGENITAL HEART DISEASE; DISEASE PREDISPOSITION; EXON; FEMALE; GERMLINE MUTATION; HEART CATHETERIZATION; HEART OUTPUT; HEART RIGHT VENTRICLE FAILURE; HUMAN; LUNG ANGIOGRAPHY; LUNG EMBOLISM; LUNG VASCULAR RESISTANCE; MISSENSE MUTATION; OVEREXERTION; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; PULMONARY VENO-OCCLUSIVE DISEASE; SYSTOLIC HEART MURMUR; THORAX RADIOGRAPHY; CHRONIC DISEASE; FATALITY; GENETIC PREDISPOSITION; GENETICS; HYPERTENSION, PULMONARY; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PHENOTYPE; PULMONARY EMBOLISM; TIME; TREATMENT OUTCOME;

ADULT; ANTICOAGULANTS; ANTIHYPERTENSIVE AGENTS; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE II; CHRONIC DISEASE; DNA MUTATIONAL ANALYSIS; FATAL OUTCOME; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; HYPERTENSION, PULMONARY; MUTATION, MISSENSE; PHENOTYPE; PULMONARY EMBOLISM; TIME FACTORS; TREATMENT OUTCOME;

EID: 84906933616     PISSN: 03412040     EISSN: 14321750     Source Type: Journal    
DOI: 10.1007/s00408-014-9580-y     Document Type: Article

References (10)

1. Hoeper MM, Mayer E, Simonneau G, Rubin LJ (2006) Chronic thromboembolic pulmonary hypertension. Circulation 113:2011-2020
2. Riedel M, Stanek V, Widimsky J, Prerovsky I (1982) Long-term follow-up of patients with pulmonary thromboembolism. Late prognosis and evolution of hemodynamic and respiratory data. Chest 81:151-158 (Pubitemid 12165545)
3. Runo JR, Vnencak-Jones CL, Prince M et al (2003) Pulmonary veno-occlusive disease caused by an inherited mutation in bone morphogenetic protein receptor II. Am J Respir Crit Care Med 167:889-894 (Pubitemid 36801778)
4. Humbert M, Deng Z, Simonneau G et al (2002) BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives. Eur Respir J 20:518-523
5. Roberts KE, McElroy JJ, Wong WP et al (2004) BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease. Eur Respir J 24:371-374 (Pubitemid 39232257)
6. Liu D, Liu QQ, Eyries M et al (2012) Molecular genetics and clinical features of Chinese idiopathic and heritable pulmonary arterial hypertension patients. Eur Respir J 39:597-603
7. Pengo V, Lensing AW, Prins MH et al (2004) Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 350:2257-2264
8. Yang X, Long L, Southwood M et al (2005) Dysfunctional Smad signaling contributes to abnormal smooth muscle cell proliferation in familial pulmonary arterial hypertension. Circ Res 96:1053-1063 (Pubitemid 40791377)
9. Rajiv DM, Nung R, Carl A et al (2003) Functional interaction between BMPR-II and Tctex-1, a light chain of Dynein, is isoform-specific and disrupted by mutations underlying primary pulmonary hypertension. Hum Mol Genet 24:3277-3286
10. Joy C, Eric A, Lora H (2012) Role of BMPR2 alternative splicing in heritable pulmonary arterial hypertension penetrance. Circulation 126:1907-1916